Page 40 - Lexaria Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lexaria Bioscience Corp.: Lexaria Appoints New Chief Financial Officer and Issues Consultant Warrants KELOWNA, BC / ACCESSWIRE / April 15, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the appointment of a new Chief Financial Officer and the issuance of share purchase warrants to third party consultants. Lexaria is pleased to announce that effective April 15, 2021, Gregory Downey will be assuming the role of Chief Financial Officer of the Company. During the past two years, Mr. Downey...

TM Powers Amari's Award-Winning Products KELOWNA, BC / ACCESSWIRE / April 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announced that its corporate client Amari Corp.'s "Everyday Calm" CBD product was named a Top CBD Product Pick by New Hope Network, host of the industry-leading Natural Products Expo conference events. Hundreds of CBD products competed to be among "New Hope Network editors' Top Picks for 2020". Eric Gricus, CEO and Founder of Amari, commented, "Amari went through an exten...

PCG Digital: Lexaria Is Expanding CBD Use Beyond Medical Applications into $2.65 Billion Marketplace New York, New York--(Newsfile Corp. - April 8, 2021) - PCG Digital -- The team at Lexaria Bioscience (NASDAQ: LEXX), a leader in cannabinoid research, has been thinking outside the box. Utilizing DehydraTECH TM, their proprietary drug delivery technology, they are showing that its benefits can enrich more than just CBD medical applications. Though they are currently executing groundbreaking work in anti-hypertension solutions, Lexaria received their first patent in 2016 for CBD-infused bevera...

Lexaria Bioscience Corp.: Lexaria to Evaluate DehydraTECH in Multiple New Markets KELOWNA, BC / ACCESSWIRE April 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, will begin important new applied research and development (R&D) study programs planned in 2021. Lexaria's new study programs will target four drug markets, including NSAIDs, nicotine replacement therapies, tetrahydrocannabinol, and erectile dysfunction. Each of the studies will evaluate the rate of absorption and speed (pharmacokineti...

PCG Digital: Could DehydraTECH CBD be Worth $3 Billion a Year to Lexaria? New York, New York--(Newsfile Corp. - March 9, 2021) - PCG Digital -- Hypertension, or high blood pressure as it's commonly known, affects over three million Americans every year and is a primary or contributing cause of death for 25% of them. On a global scale, hypertension kills roughly 7.6 million people per year. Lexaria Bioscience, a Canadian biotech firm specializing in cannabinoid research, is hoping to change those numbers. DehydraTECH CBD, the company's revolutionary oral deliverable for hypertension sufferer...